Buying Blueshift for $13M, MDS Adds Whole-Well, High-Speed Imaging Ability | GenomeWeb
MDS Analytical Technologies announced last week that it has acquired fluorimetry-based screening platform manufacturer Blueshift Biotechnologies for $13 million in a bid to expand its cellular-analysis chops and strengthen its global sales and service muscle.
MDS said it will try to leverage Blueshift’s IsoCyte technology to offer customers more complete high-content screening and high-content analysis products, an MDS official told CBA News last week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: modern European bison analysis, phased diploid genome assembly algorithms, and more.

Actress Jennifer Lopez is working with NBC on a CRISPR-inspired television show, according to the Hollywood Reporter.

Researchers trace the origin of one human papillomavirus lineage to Neanderthals or Denisovans, Vox reports.

The BabySeq project faces lower-than-expected enrollment rates, according to ScienceInsider.